Skip to main navigation
Skip to search
Skip to main content
Prinses Máxima Centrum Home
Nederlands
English
Home
Profiles
Research Groups
Equipment
Research output
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Somatic activating ARAF mutations in Langerhans cell histiocytosis
David S. Nelson
, Willemijn Quispel
, Gayane Badalian-Very
,
Astrid G.S. Van Halteren
, Cor Den Van Bos
, Judith V.M.G. Bovée
, Sara Y. Tian
, Paul Van Hummelen
, Matthew Ducar
, Laura E. MacConaill
, R. Maarten Egeler
, Barrett J. Rollins
Research output
:
Contribution to journal
›
Article
›
peer-review
158
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Somatic activating ARAF mutations in Langerhans cell histiocytosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Somatics
100%
Langerhans Cell Histiocytosis
100%
Mitogen-Activated Protein Kinase
75%
Histiocyte
50%
In Vitro
25%
Allele
25%
Signal Transduction
25%
Exome Sequencing
25%
Phosphotransferase
25%
Kinase Signaling
25%
Mouse Embryo
25%
Vemurafenib
25%
Mitogen Activated Protein Kinase Kinase
25%
Fibroblast
25%
Keyphrases
Langerhans Cell Histiocytosis
100%
Histiocytes
50%
Extracellular Signal-regulated Kinase Pathway
50%
Activating mutation
25%
Whole Exome Sequencing
25%
In(III)
25%
Mitogen-activated Protein Kinase
25%
Inhibitor Therapy
25%
Genetic Causes
25%
Highly Active
25%
Mouse Embryonic Fibroblasts
25%
Kinase Domain
25%
Vemurafenib
25%
Pathway Activation
25%
BRAF Inhibitor (BRAFi)
25%
Targeted Inhibitors
25%
Compound mutation
25%
Extracellular Signal-regulated Kinase Signaling Pathway
25%
Immunology and Microbiology
Langerhans Cell
100%
Wild Type
50%
Histiocyte
50%
Allele
25%
Signal Transduction
25%
Whole Exome Sequencing
25%
Mitogen
25%
Fibroblast
25%
Pharmacology, Toxicology and Pharmaceutical Science
Langerhans Cell Histiocytosis
100%
Mitogen Activated Protein Kinase
75%
Phosphotransferase
25%
Vemurafenib
25%
Mitogen Activated Protein Kinase Kinase
25%